Introduction
β-N-methylamino-l-alanine (BMAA) is a neurotoxic amino acid produced by cyanobacteria, potentially also produced by other microorganisms such as diatoms (Jiang et al. 2014; Réveillon et al. 2016) . Cyanobacteria of the genus Nostoc are harboured in specialised coralloid roots of cycads, where they live in symbiosis . Human consumption of foods derived from cycads and animals that feed on cycads has been implicated in the development of amyotrophic lateral sclerosis/parkinsonism dementia complex (ALS/PDC) among the Chamorro people of Guam (Whiting 1963; Cox et al. 2003; Murch et al. 2004; Banack et al. 2006) . BMAA has been shown to cause neurological damage in vitro (Rao et al. 2006; Lobner 2009 ) and in vivo Karamyan and Speth 2008; Nunn 2009; de Munck et al. 2013; Karlsson et al. 2015; Cox et al. 2016a) .
Cyanobacteria produce a wide range of toxic compounds, including hepatotoxins and neurotoxins . When isolated and grown as free-living organisms, the symbiotic cyanobacteria from cycads can produce BMAA, which accumulates in cycads . Furthermore, analysis of a wide range of non-symbiotic free-living cyanobacteria suggests that BMAA production Abstract Chronic dietary exposure to the cyanobacterial toxin β-N-methylamino-l-alanine (BMAA) triggers neuropathology in non-human primates, providing support for the theory that BMAA causes a fatal neurodegenerative illness among the indigenous Chamorro people of Guam. However, since there are two stereoisomers of BMAA, it is important to know if both can occur in nature, and if so, what role they might play in disease causation. As a first step, we analysed both BMAA enantiomers in cyanobacteria, cycads, and in mammals orally dosed with l-BMAA, to determine if enantiomeric changes could occur in vivo. BMAA in cyanobacteria and cycads was found only as the l-enantiomer. However, while the l-enantiomer in mammals was little changed after digestion, we detected a small pool of d-BMAA in the liver (12.5%) of mice and in the blood plasma of vervets (3.6%). Chiral analysis of cerebrospinal fluid of vervets and hindbrain of mice showed that the free BMAA in the central nervous system was the d-enantiomer. In vitro toxicity investigations with d-BMAA showed toxicity, can occur worldwide (Cox et al. 2005; Metcalf et al. 2008; Esterhuizen and Downing 2008; Spacil et al. 2010) . Vega and Bell (1967) and Vega et al. (1968) crystallised the l-enantiomer of BMAA from an alcohol extract of Cycas micronesica Hill (Cycadaceae) seeds. At that time, no d-BMAA was isolated and it was concluded that d-BMAA was not present in cycads. Furthermore, although l-BMAA has been shown to be toxic in a range of test systems, the limited research into the toxicity of synthetic d-BMAA suggested that it has little or no toxicity (Vega et al. 1968; Polsky et al. 1972; Nunn et al. 1987) . The implications of exposure to BMAA from the environment and its association with human disease are considered to be a result of exposure to the l-enantiomer of BMAA.
A variety of analytical methods are available for the analysis of BMAA in a range of matrices (Cox et al. , 2005 Metcalf et al. 2008; Pablo et al. 2009 ) including HPLC-FLD, LC-MS, LC-MS/MS, GC-MS, and amino acid analyser (e.g. Banack et al. 2007; Esterhuizen and Downing 2008) . However, these methods do not discriminate between the l-and d-enantiomers of BMAA, and at present, little information is available as to which enantiomers of BMAA occur naturally. An HPLC method employing pre-derivatisation of l-and d-BMAA as o-phthaldialdehyde derivatives worked well, successfully separating synthetic standards (Euerby et al. 1989) . To provide useful information on the presence of this amino acid in environmental and clinical materials, chiral methods may become important to understand whether d-BMAA exists in nature, and also whether this can be related to toxicity events and human disease.
Racemisation and enantiomeric changes to amino acids are a well-recognised phenomenon, with alterations of pH, time, and temperature affecting this process to differing degrees (Friedman 2010) . As the Chamorro people of Guam consume BMAA in free and protein-bound forms, derived from cycads (Cheng and Banack 2009) , few if any studies have considered the potential for enantiomeric changes to this amino acid in vivo.
The occurrence of d-amino acids has been well documented in the bacterial Domain, with d-amino acids known to occur in secondary metabolites and peptides, including cyanobacterial toxins . In the mammalian brain, d-amino acids also occur, with d-serine and d-aspartic acid being produced by racemases that change the enantiomeric configuration of the l-amino acid. Such d-amino acids play important roles in mammalian neurochemistry (Kim et al. 2010; Baumgart and Rodriguez-Crespo 2008; Krashia et al. 2016) . Although d-amino acids are important in neurochemistry, their occurrence and the presence of enzymes involved in their racemisation and metabolism can be found in other tissues. The presence of d-glutamate in the heart (Ariyoshi et al. 2017) , and d-aspartate and d-serine in tissues such as the testes, kidney, skin, and skeletal system have been documented (Guevara and Mani 2016; Ito et al. 2016) .
The purpose of this study was to develop a method to analyse naturally occurring enantiomers of BMAA and to determine whether any enantiomeric changes could occur during digestion in the mammalian gut after oral exposure. Furthermore, testing of d-BMAA in in vitro toxicity systems was carried out. Such information may prove useful in understanding the fate and the potential toxicities of BMAA and its relationship to neurological disease.
Materials and methods

Collection of cycads, growth of cyanobacteria, and BMAA extraction
Cycad seeds from C. micronesica Hill were collected at the Montgomery Botanical Garden, Coral Gables, Florida and transported to the Brain Chemistry Labs for extraction. The fleshy sarcotesta was removed and the rigid sclerotesta was cut to expose the gametophyte. The gametophyte was removed and cut into small pieces for amino acid extraction. Free amino acids were extracted three times using 0.1 M trichloroacetic acid (TCA) with ultrasonication at room temperature at a concentration of 61 mg dry weight per ml. The TCA extract was ultrafiltered (0.22 μm Millipore Ultrafree MC), dried, and stored at 4 °C until analysed. An isolate of Nostoc sp., isolated from a C. micronesica coralloid root, was maintained in BG11 medium supplemented with sodium nitrate for 4 years at 25 °C and with cool white fluorescent light at 25 μE m −2 s −1
, with periodic sub-culturing and freeze-drying of biomass. A collection underwent extraction in 0.1 M TCA with ultrasonication at room temperature, prior to ultrafiltration and storage at 4 °C.
BMAA administration, plasma sampling, and experimental design
Concerning mammalian samples for chiral testing, a limited number of specimens were available from two independent studies investigating the toxicology, metabolism, and organ distribution of BMAA. For mice studies, animals were sacrificed, allowing samples of brain and liver to be obtained for analysis, whereas vervets were not sacrificed. Consequently, post-digestion in vervets, samples were obtained from blood plasma, and for the central nervous system, CSF was collected. Although different samples were obtained from test organisms, they do represent collections post-digestion and in the central nervous system for both species.
Mice were bred and maintained under standard conditions (14 h light:10 h dark, 18-23° C temperature and 40-60% humidity, acidified H 2 O, and sterilized pine shaving bedding and cages changed weekly) in the Research Animal Facility at The Jackson Laboratory. The nutritionally complete 6% fat NIH 31-based 5K52 diet (LabDiet, St. Louis, MO) supplemented with or without l-BMAA was provided ad libitum in a 6-month chronic dosing experiment (25 mg/kg/day) in C57BL/6J background mice (JR#004435, The Jackson Laboratory). The pre-ground 5K52 diet was mixed with a 1 g/100 ml (1%) stock solution of l-BMAA to a final concentration of 20.83 mg per 100 grams of diet, formed into patties and dehydrated overnight in a low-heat dehydrating oven (45 °C) and stored at −20 °C until use. Diet was supplied to the mice (4 per cage) in the food hopper and was replaced weekly. Dosing was based on a short dietary exposure study published by Cruz-Aguado et al. (2006) .
Animal care was in accordance with the National Research Council, Guide for the Care and Use of Laboratory Animals (1996) , and approved by the Institutional Animal Care and Use Committee (protocol #01006). Mice were euthanized by cervical dislocation, and liver and hindbrain were excised and stored at −80 °C. For extraction, once thawed, subsamples of the hindbrain and liver from a BMAA-dosed mouse were extracted with 100 µl 0.1 M TCA (Sigma, St. Louis, MO). The extract was dried in a Speedvac (Thermo Savant Speedvac Plus, SC250DDA), and the residue resuspended with 50 µl 2 mM CuSO 4 in Millipore DirectQ (DQ) water or 100 µl 2 mM CuSO 4 in DQ water for liver and hindbrain extracts, respectively. The aqueous copper sulphate extracts were directly injected into the chiral HPLC system and fractions collected. The collected fractions were derivatised with 6-aminoquinolyl-N-hydroxysuccinimidyl carbamate (AQC) and analysed by UPLC-MS/MS. Vervets (Chlorocebus sabaeus) obtained from the Behavioural Science Foundation (BSF) in St. Kitts, West Indies were fed l-BMAA. Animal care was in accordance with the National Research Council, Guide for the Care and Use of Laboratory Animals (1996) , and approved by the Institutional Animal Care and Use Committee.
The subjects used in this study were three adult male vervets (4.5 kg) that were housed in outdoor social groups. Each outdoor enclosure measured approximately 30 m 2 and contained perches and play structures. Subjects were always housed in social groups except during sampling. Vervets were maintained on a modified diet, routinely fed 2 days of primate chow (Teklad NIB primate diet, Madison, WI, USA) per week and fresh produce only on other days (n = 5). Slight variation occurred at times when produce was limited. l-BMAA was applied as a powder (70 mg/kg body weight) to a hollowed-out piece of fruit, and offered to the animals. No control animals were included and prior exposure to BMAA was considered to be minimal, and based on the dose of BMAA administered, considered to be unlikely to influence the concentrations in dosed animals. Animals were dosed orally every day and the dosing took place over 10 days with CSF and plasma collected under ketamine HCl (10 mg/kg) anaesthesia at 240 and 244 h, respectively. CSF was collected directly into cryovials and frozen, and blood was collected in heparinised tubes which were centrifuged, prior to removal of the plasma and stored frozen. Vervets were not sacrificed for this study. One hundred microliters of the plasma and CSF from a BMAA-dosed vervet were dried in a Speedvac, prior to resuspension to the same volume with 2 mM aqueous copper sulphate and fraction collection by chiral HPLC. The collected fractions were derivatised with AQC and analysed by UPLC-MS/MS.
Analysis of BMAA by UPLC-UV-MS
BMAA was detected in the TCA extracts by comparison with a triple crystallised l-BMAA standard (P. B. Nunn), a dl-BMAA mixture from Thesis chemistry (Cambridge, Ontario, Canada) and an l-BMAA standard (Sigma B-107, St. Louis, MO) after derivatisation with AQC by UPLC-UV/MS using the methods in Banack et al. (2007) . Extracts found to contain BMAA according to retention time and molecular weight were separated by chiral HPLC.
Chiral HPLC analysis and fractionation of TCA extracts
Chiral separation of l-and d-BMAA was achieved using a Chirex 3126 chiral HPLC column (Phenomenex; 250 × 4.6 mm i.d.) with mobile phases of 2 mM CuSO 4 in water (eluent A) and 2 mM CuSO 4 in 15% (v/v) aqueous acetonitrile (eluent B) using a Waters 717 autosampler and Waters 1525 binary pump. A gradient elution was used: 100% A to 70% B from 0 to 13 min, curve 10, followed by a wash from 13 to 16 min of 70% B before returning to 100% A at 17 min, with a total run time of 35 min to condition the column prior to the next injection. Flow was maintained at 1.2 ml/min throughout. Detection was performed using a 2487 UV detector (Waters) at a wavelength of 254 nm. The gradient was tested using a mix of 17 standard amino acids (Pierce #NCI0180) plus the l-BMAA isomers/ enantiomers, l-2,4-diaminobutyric acid (l-DAB; #32830, Sigma, St. Louis, MO), N-(2-aminoethyl)glycine (AEG; A1153 TCI America; Banack et al. 2012) , d-BMAA (P.B. Wyatt), and d-DAB (P.B. Nunn).
Based on the amount of BMAA in the cycad TCA extract, a 1/50 dilution with 2 mM CuSO 4 in water was prepared and separated by chiral HPLC, to not overload the chiral column. Fractions corresponding to the retention time of l-BMAA, between l-and d-BMAA, and d-BMAA were collected by hand (approximately 1 ml per fraction). Collected cycad fractions were analysed by UPLC-MS/ MS after derivatisation with AQC. Separately, after drying in the Speedvac, the residue of each fraction was reconstituted with 100 µl 20 mM HCl and derivatised with AQC for UPLC-MS/MS analysis.
The TCA extract from the cyanobacterium was dried, resuspended to the same volume with 2 mM CuSO 4 in water, and injected directly onto the chiral HPLC column. Nine separate blank injections (2 mM CuSO 4 in water) and nine cyanobacterial extract injections, each of 10 µl, were performed and the fractions collected by hand (approximately 1 ml per fraction). The fractions were freeze-dried and each resuspended in 100 µl 20 mM HCl. The nine chiral fractions from the blank and cyanobacterial injections were, respectively, pooled, to allow concentration of the free BMAA fractionated from the TCA extract, in comparison with a set of blank injections. The copper present in the pooled extracts was precipitated by addition of 10 µl 12 M NaOH for the cyanobacterial extract and the blank, to simplify the extract containing a low amount of BMAA for subsequent analysis. The suspensions were centrifuged to remove copper and the supernatants transferred to clean microcentrifuge tubes. To each cleared supernatant, 10 µl 12 M HCl were added to neutralise the sodium hydroxide and the solutions again freeze-dried. After drying, the residue was resuspended with 100 µl 20 mM HCl and the solutions were derivatised with AQC. Subsequently, the derivatised amino acids of both the blank and the cyanobacterial TCA chiral fractions were dried and resuspended in DQ water equivalent to a 3× concentration step for UPLC-MS/ MS analysis.
UPLC-MS/MS analysis of BMAA
AQC-derivatised samples of TCA extracts or fractions after collection from the chiral HPLC were run on a triple quadrupole UPLC-MS/MS system (Thermo Scientific Finnigan TSQ Quantum UltraAM, San Jose, CA) after separation with a Waters Acquity-UPLC system with a Binary Solvent Manager, Sample Manager, and a Waters AccQTag Ultra column (part # 186003837, 2.1 × 100 mm) at 55 °C. Separation was achieved using gradient elution at 0.65 ml/min with 0.1% formic acid in water (eluent A) and 0.1% formic acid in acetonitrile (eluent B): 0.0 min 99.1% A; 0.5 min 99.1% A curve 6; 2 min 95% A curve 6; 3 min 95% A curve 6; 5.5 min 90% A curve 8; 6 min 15% A curve 6; 6.5 min 15% A curve 6; 6.6 min 99.1% A curve 6; and 8 min 99.1% A curve 6. Nitrogen gas was supplied to the heated electrospray ionisation (HESI) probe with a nebulising pressure of 40 psi and a vaporiser temperature of 400 °C. The mass spectrometer was operated under the following conditions: the capillary temperature was set at 270 °C, capillary offset of 35, tube lens offset of 110, aux gas pressure of 35, spray voltage of 3500 V, source collision energy of 0, and multiplier voltage of −1719 V. A divert valve was used during equilibration and cleaning phases of the gradient. The second quadrupole was pressurised to 1.0 mtorr with 100% argon. The precursor ion was set for m/z 459 which excludes in the first quadrupole ions of all other masses from analysis. During BMAA analysis of cycad extracts, collision-induced dissociation (CID) was achieved in the second quadrupole using the following transitions: m/z 459 to m/z 119 CE 21; m/z 459 to m/z 289 CE 17; and m/z 459 to m/z 171 CE 38. The resultant four product ions (m/z 119, 289, 171, 188) were scanned by the third quadrupole, subsequently detected, and their relative abundances quantified in comparison with AQC-derivatised N-(2-aminoethyl) glycine (AEG), l-BMAA, and l-2,4-diaminobutyric acid (l-DAB) standards. For cyanobacterial extracts, the precursor ion of m/z 459 was monitored for CID daughter ions of m/z 171, 289, 119, 258 (BMAA, CE 21 eV), 214 (AEG, CE 35 eV), and 188 (DAB, CE 38 eV), with the latter three being qualifier ions for the different isomers. The quantification of l-and d-BMAA was carried out using l-BMAA standards in water using the transition 459 > 171. LOD (48 fmol) and LOQ (0.48 pmol) were calculated using the EPA method detection level (Betz et al. 2011; Banack et al. 2014) .
In vitro toxicity assessment of d-BMAA
Timed pregnant Swiss Webster mice were obtained from Charles River Laboratories (Wilmington, DE, USA). Mixed cortical cell cultures containing neurons and astrocytes were prepared from foetal (15-16 day gestation) mice as described previously (Lobner 2000) . The mice were handled in accordance with a protocol approved by the institutional animal care committee. All experiments were performed on mixed cultures 13-15 days in vitro (DIV). Toxicity was induced by exposure to BMAA for 24 h in media as for plating except without serum. All exposure media contained 26 mM NaHCO 3 , as it has been shown previously that HCO 3 − is required for expression of NMDA receptor-mediated BMAA toxicity (Weiss and Choi 1988) . Cell death was assessed by the measurement of lactate dehydrogenase (LDH), released from damaged or destroyed cells, in the extracellular fluid 24 h after the beginning of the insult. Blank LDH levels were subtracted from insult LDH values and results normalized to 100% neuronal death caused by 500 μM NMDA. Control experiments have shown previously that the efflux of LDH occurring from either necrotic or apoptotic cells is proportional to the number of cells damaged or destroyed (Koh and Choi 1987; Lobner 2000) . In none of the conditions, in the studies presented was there any evidence of glial cell death observed (assessed by trypan blue staining). Therefore, results are presented as percent neuronal death, determined by subtracting blank LDH release levels from experimental condition LDH release and dividing by the total LDH release levels induced by exposure to NMDA and then expressing as a percentage. Cells were not counted when plating as astrocytes are present which are dividing cells, so the initial plating is not necessarily correlated with final cell numbers. All compounds were made up in water at a stock concentration 1000× the final concentration; therefore, vehicle controls were not believed to be necessary. Blank LDH levels mean LDH release in cultures without drug treatment.
Results
Using chiral HPLC, l-and d-BMAA enantiomer standards could be clearly distinguished from standard amino acids and the BMAA isomers, the achiral N-(2-aminoethyl)glycine (retention time 2 min), d-2,4-diaminobutyric acid (retention time 4 min), which roughly co-eluted with l-2,4-diaminobutyric acid (Fig. 1a) . The difference in retention time between the two BMAA enantiomers was approximately 1 min, with l-BMAA eluting from the column before d-BMAA (Fig. 1b) . UPLC-UV/MS and MS/ MS analyses showed that the TCA extract from seeds of C. micronesica contained BMAA. Analysis of a TCA extract from the cycad gametophyte by chiral HPLC indicated peaks with the same retention time as l-BMAA, but not for d-BMAA (Fig. 1c) . As the sensitivity of the chiral method was approximately 100 times less than standard amino acid analysis techniques employed for BMAA, the chiral HPLC method was developed and used as a sample preparation technique to (a) remove interfering compounds in the analysis of BMAA, (b) to separate and determine what enantiomers of BMAA are present, and (c) as a multiple fractionation tool to collect enantiomers (Fig. 2) . The cycad extract (Fig. 1c) was fractionated into three fractions from 7.5 to 8.2, 8.3-8.7, and 8.8-9.4 min by chiral HPLC. These fractions were then analysed by UPLC-MS/MS to confirm the presence of BMAA enantiomers. In the l-BMAA fraction, a peak at 4.95 min was observed in the fractionated cycad extract, consistent with the L-BMAA standard (Fig. 3a) . The peak collected between l-and d-BMAA showed a trace amount of BMAA, and although a peak was observed in the third fraction, analysis of the ratios of daughter ions indicated that d-BMAA was not present or was below the limits of detection ( Fig. 3b; Table 1 ). In comparison with a BMAA standard, retention times and daughter ions were consistent for BMAA in the first two fractions. The presence of trace amounts of BMAA in the dl-fraction was considered to be carry-over from the collection of the l-enantiomer fraction. Although slight shifts in retention time were observed from day to day, no significant retention time shifts were noted. Before fractionation, the chiral HPLC system was calibrated with fresh l-and d-BMAA standards and these time windows were used for the fractionation of unknown samples. Therefore, we do not expect to witness cross-contamination of l-and d-BMAA in fractions.
As the concentration of BMAA in cycads is much greater than that in cyanobacteria, the chiral method was used to collect multiple fractions with retention times corresponding to those of l-and d-BMAA from a symbiotic Nostoc TCA extract, in comparison with an identical set of Fig. 2 Schematic overview of the chiral fractionation procedure blank injections. Samples were purified and concentrated and analysed by LC-MS/MS after derivatisation with AQC. UPLC-MS/MS analysis of blank fractions showed no BMAA enantiomers to be present, whereas the presence of l-BMAA was confirmed in the TCA extract from the Nostoc symbiont ( Fig. 3c; Table 1 ). Based on the variation in daughter ion ratios for cycads and cyanobacteria (Table 1) , only l-BMAA was confirmed with the ion ratios for d-BMAA being outside that expected for synthetic standards.
Chiral analysis was performed on tissues from animals dosed with l-BMAA. Chiral HPLC analysis of the stock l-BMAA showed that the preparation administered was exclusively the l-enantiomer for both the BMAA administered to mice and vervets (this study; Cox et al. 2016b) . Analysis of the free BMAA in these tissues showed that the mouse liver and the vervet plasma were predominantly the l-enantiomer (Fig. 4; Table 2 ), showing little, if any, racemization of l-BMAA occurs before its appearance in serum or liver. In contrast, Fig. 5 shows that the majority of BMAA determined by UPLC-MS/ MS analysis of the chiral fractions in brain or CSF was the d-enantiomer (Table 2) . As enantiomeric mixtures were observed, the percentage of l-BMAA and d-BMAA in each extract was assessed. Using the peak areas from the MS/MS chromatograms to calculate the amount of BMAA in each enantiomeric fraction, the liver and plasma contained predominantly l-BMAA (plasma As the potential long-term toxicity of d-BMAA is little understood or not known, in vitro experiments were carried out with d-BMAA. Both enantiomers of BMAA were shown to cause neuronal cell death in a dosedependent manner (Fig. 6a, b) , with significant neuronal death occurring at mM concentrations. When neuronal cell death was measured in the presence of MK801 (Fig. 6c, d ), this NMDA receptor agonist prevented neuronal cell death in the presence of l-BMAA but not in the presence of d-BMAA. When neurons were incubated with d-BMAA (Fig. 6e) , neuronal cell death could be prevented using the AMPA receptor agonist NBQX, but not the calcium permeable AMPA receptor agonist NASPM.
Discussion
The discovery of BMAA and its toxic properties more than four decades ago have inspired a wealth of scientific research. To date, only the l-BMAA enantiomer has been crystallised from cycad extracts and the synthetically produced d-BMAA enantiomer has been considered non-toxic (Vega and Bell 1967; Vega et al. 1968; Polsky et al. 1972; Nunn et al. 1987; Nunn 2009 ). The finding that BMAA is produced by cyanobacteria (Cox et al. , 2005 ) raises the question of the possible presence of the d-BMAA enantiomer in cyanobacteria, particularly because cyanobacteria are well known to produce and incorporate d-amino acids into other compounds . For example, d-alanine and d-glutamic acid are common components of the cyanobacterial heptapeptide microcystins . To understand the environmental occurrence of BMAA and to better understand the relationship between cycads and their cyanobacterial symbionts, we developed a chiral HPLC method to determine which BMAA enantiomers occur in cycads and to determine whether small concentrations of previously undetected d-BMAA may be present (Vega and Bell 1967; Vega et al. 1968) . Although d-BMAA was not observed in the cycad extract in the original work of Vega and Bell (1967) and Vega et al. (1968) , its absence may have been due to the sample preparation methods used. If d-BMAA was present in the cycad extracts, the likelihood of confirming its presence would be increased if chiral HPLC was used. Since exposure to BMAA has been implicated in the development of amyotrophic lateral sclerosis/parkinsonism dementia complex (ALS/ PDC) on Guam Murch et al. 2004; Cox et al. 2016a ) and BMAA has been identified in the brains of ALS and Alzheimer's patients in USA and Canada (Murch et al. 2004; Pablo et al. 2009 ), a greater understanding of l-and d-BMAA enantiomers might shed further light on disease aetiology.
Fractionation of a TCA extract from Nostoc isolated from Guamanian cycad coralloid root and a TCA extract of cycad gametophyte tissue did not indicate the presence of d-BMAA, whereas the l-enantiomer was positively identified using the chiral method described herein. The use of chiral HPLC as a fractionation tool had certain advantages due to the fact that multiple fractions could be iteratively collected and combined to increase the potential concentration of BMAA for later mass spectrometric analysis. Furthermore, this fractionation method also removed interfering compounds from the sample matrix, thus simplifying the mass spectrometric analysis and providing separation of BMAA enantiomers from the structural isomers l-2,4-DAB (Banack et al. 2010 ), d-2,4-DAB, and the achiral AEG (Banack et al. 2012) . This is largely because only two approximate 1 min windows were collected resulting in a large number of compounds being retained by the chiral column or eluting at a different time which would not be present in the fractions during subsequent analysis. The chiral method shown here will be useful for investigating which free BMAA enantiomers exist in a wide range of plant, cyanobacterial, and clinical materials.
Amyotrophic lateral sclerosis/parkinsonism dementia complex among the Chamorro people has been linked to high concentrations of BMAA in their diet Bradley and Mash 2009; Banack and Murch 2009; Cox et al. 2016a ). In mammals, food is processed within the mouth and stomach, with the potential to alter the enantiomeric ratio of l-and d-amino acids due to changes in pH and temperature (Friedman 2010) , although no changes were noticed with l-or d-BMAA stored in HCl (data not shown). Since the traditional Chamorro diet included BMAA-containing washed cycad flour and flying foxes Banack et al. 2006; Cheng and Banack 2009) , there is a possibility that BMAA enantiomers present in their food may be transformed to a racemic mixture during digestion. Analysis of mouse liver and vervet plasma indicated that after oral administration and digestion of l-BMAA, the majority of this amino acid was still present as the l-enantiomer. In contrast, d-BMAA was the only free enantiomer found in the central nervous system of both mice and vervets. Since the d-enantiomer has not previously been described in nature, then a mechanism for the interconversion between BMAA enantiomers in mammals might exist. Within the mammalian brain, enzymes such as serine racemase [EC.5.1.1.18] are present that racemise l-serine to d-serine, which is then used as a neurotransmitter (Baumgart and Rodriguez-Crespo 2008) . A number of amino acids are known to affect the activity of this enzyme (Dunlop and Neidle 2005) and BMAA may be a substrate for or affect the activity of this enzyme. If BMAA were shown to interfere with serine racemase, it could alter the delicate balance of amino acids in the central nervous system. Furthermore, incorporation of l-BMAA into proteins can be blocked by l-serine, suggesting that these two amino acids may have metabolic, as well as structural similarities (Dunlop et al. 2013) .
A further consideration is whether l-or d-BMAA is actively transported into the brain. Our analyses indicate that the l-enantiomer is found in the circulatory system, whereas the d-enantiomer is the free enantiomer in the central nervous system. The transportation and uptake of BMAA into the brain are considered to occur through the L1 transport system for large neutral amino acids, and although inefficient, BMAA was observed to accumulate in the brain (Duncan et al. 1991; Xie et al. 2013 ). This uptake occurs as a result of the essentially uncharged nature of BMAA at pH 7.4 (Nunn and Ponnusamy 2009), along with leucine, valine, methionine, histidine, isoleucine, tryptophan, phenylalanine, and threonine (Bradley 2009) . It has previously been demonstrated that the toxic effects of BMAA can be inhibited by leucine in Drosophila (Zhou et al. 2009 ) and in rats (Smith et al. 1992 ) which supports the suggestion that BMAA may be transported across the blood brain barrier by the L1 transport system. Work by Liu et al. (2009) has discovered a second transport system (X c − ) which is also inhibited by BMAA, and it is possible that BMAA may also cross cell membranes using this system. Therefore, it would seem unlikely that the d-enantiomer would be actively transported, as evidenced by the fact that serine racemase is present within the central nervous system to convert l-to d-serine. This reasoning, along with the data showing l-BMAA in the blood plasma and liver versus d-BMAA in the brain and CSF, suggests that the free d-BMAA is produced within the brain itself.
A second racemase in the brain, aspartate racemase [EC.5.1.1.13] produces d-aspartic acid, which is an endogenous ligand for NMDA receptors (Kim et al. 2010) . The presence of a number of racemases and d-BMAA in the brains and CSF of mice and vervets, respectively, raises a further question concerning what other non-protein amino acids may be converted from their l-to d-enantiomers, which may or may not cause adverse effects. Furthermore, it is possible that other racemases in addition to serine-and aspartate racemase may exist in the mammalian brain, having the potential to racemise l-to d-BMAA.
Based on the preliminary in vitro toxicological studies carried out here, d-BMAA does appear to have some neurotoxicity, although via a different mechanism to that observed with l-BMAA. Further studies examining the toxicity of d-BMAA are required to determine whether enantiomeric changes to BMAA result in neurological deficits. Chiral HPLC analysis of human brains known to contain BMAA may shed some light on which of these scenarios is more likely. A third possibility is that deficiencies in the serine racemase enzyme itself may constitute a risk factor for neurodegeneration.
The finding that l-BMAA can be converted from the lto d-enantiomer raises interesting questions concerning the aetiology of sporadic ALS, and further studies to determine the molecular mechanisms which interconvert this amino acid may shed new light on the causes of ALS and its association with neurotoxic amino acids.
